Federal Register / Vol. 65, No. 79 / Monday, April 24, 2000 / Notices 21775

breast cancer development and

progression and may provide targets for

anti-cancer therapy. The inventors have

identified a novel gene from the

amplified region, named MB1, which

has no homology to any known genes.

MB1 is amplified in about 9% of

primary breast tumors and is

overexpressed in breast cancer cell lines

with amplification. MB1 may define a

critically important breast cancer gene

which could have significance for

development of improved diagnostics

against breast cancer.

The Use of Recombinant Cholera ToxinB for the Treatment of Inflammatory

Bowel Disease

Warren Strober, Monica Boirivant, Ivan

J Fuss, Brian L Kelsall (NIAID)

Serial No. 60/165,111 filed 12 Nov 1999

The present invention provides

methods of treating or preventing

inflammation in a subject, comprising

administering to the subject an effective

amount of cholera toxin subunit B (CT–

B). In particular, the present invention

provides methods of decreasing the

activity of interferon-gamma in a

subject, decreasing the activity of IL–12

in a subject, and treating or preventing

a Th1 T-cell mediated autoimmune

disorder.

Dated: April 18, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–10181 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Invention

Availability for Licensing: ‘‘Therapeutic

and Diagnostic Antibodies and

Immunotoxins to a Mutant Form of

Epidermal Growth Factor Receptor,

Designated ‘‘EGFRVIII’’, Which is

Highly Expressed in Glioblastomas,

Carcinomas of the Breast and Ovary,

and Non-Small Cell Lung Carcinomas’’

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

ADDRESSES: Licensing information and a

copy of the U.S. patent application

referenced below may be obtained by

contacting J. R. Dixon, Ph.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804 (telephone 301/

496–7056 ext 206; fax 301/402–0220; EMail: jd212g@NIH.GOV). A signed

Confidential Disclosure Agreement is

required to receive a copy of any patent

application.

SUPPLEMENTARY INFORMATION:

Invention Title: ‘‘Anti-EGFRvIII ScFvs

with Improved Cytotoxicity and Yield,

Immunotoxins Based Thereon, and

Methods of Use Thereof’’.

Inventors: Drs. Ira H. Pastan (NCI),

Richard Beers (NCI), Partha S.

Chowdury (NCI) and Darell Bigner (EM).

USPA SN: [= DHHS Ref. No. E–009–00/

0]—Filed with the U.S.P.T.O. on

January 25, 2000.

Abstract

A mutant form of the epidermal

growth factor receptor, designated

‘‘EGFRvIII,’’ is highly expressed in some

50–60% of glioblastomas and has also

been shown to be present in some 70–

80% of carcinomas of the breast and

ovary, and about 16% of non-small cell

lung carcinomas. The mutation consists

of an in-frame deletion of exons 2–7

near the amino-terminus of the

extracellular domain which results in

the expression of an EGFR mRNA with

an 801 base deletion. The mutant

protein contains a new glycine codon at

the splice junction. The receptor has

constitutive tyrosine activity that

enhances the tumorigenicity of

glioblastomas in vivo. Because of the

tumor-specific extracellular sequence,

the mutant receptor is an attractive

potential target for cancer therapy,

particular via the use of immunotoxins

(e.g., MR1(Fv)–PE38).

Technology

The technology claimed in the patent

application is directed to antibodies to

an epidermal growth factor receptor

known as EGFRvIII. In particular, the

invention provides an antibody,

designated MR1–1, which mutates MR1

in the CDR3 of the (VH) and (VL) chains

to provide an antibody with especially

good cytotoxicity. The described

polypeptides can be coupled, attached

or otherwise linked to an effector

molecule, therapeutic moiety, or

detectable label. The patent application

provides nucleic acid molecules

encoding the polypeptides with a

mutated antibody variable heavy (VH)

chain regions or a mutated light chain

(VL) region, or both. The invention also

provides methods of killing a cell

bearing an antigen comprising

contacting the cell with an

immunotoxin comprising a toxic moiety

and a targeting moiety. The Antibodies

and Immunotoxins of claimed in this

patent application could be used to

develop cancer therapeutics and

diagnostics.

The above mentioned Invention is

available, including any available

foreign intellectual property rights, for

licensing.

Dated: April 17, 2000.

Jack Spiegel,

Director, Division of Technology Development

& Transfer, Office of Technology Transfer.

[FR Doc. 00–10182 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary &

Alternative Medicine; Notice of Meeting

Pursuant to Section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the National Advisory

Council for Complementary and

Alternative Medicine (NACCAM).

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the grant

applications and/or contract proposals,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Advisory

Council for Complementary and Alternative

Medicine.

Date: May 8–9, 2000.

Open: May 8, 2000, 8:30 am to

adjournment.

Agenda: The agenda includes the

Director’s Report and presentation of

NCCAM’s Draft Strategic Plan, Development

of Trans-NIH Health

21776 Federal Register / Vol. 65, No. 79 / Monday, April 24, 2000 / Notices

Disparities, Public Comments, and other

business of the Council. Closed: May 9,

2000, 8:30 am to adjournment. FP1-2

Agenda: To review and evaluate grant

applications and/or proposals.

Place: NIH Neuroscience Office Building,

6001 Executive Boulevard, Conference Room

C, Rockville, MD 20852.

Contact Person: Richard Nahin, Executive

Secretary, National Center for

Complementary and Alternative Medicine,

National Institutes of Health, 9000 Rockville

Pike, Room 5B36, Bethesda, MD 20892; 301–

594–2013.

The public comments session is

scheduled from 1:15 pm to 2:15 pm.

Each speaker will be permitted 5

minutes for their presentation.

Interested individuals and

representatives of organizations are

requested to notify Dr. Richard Nahin,

National Center for Complementary and

Alternative Medicine, NIH, 31 Center

Drive, (MSC 2182), Building 31, Room

5B36, Bethesda, Maryland, 20892, 301–

594–2013, Fax: 301–480–9500.

Letters of intent to present comments,

along with a brief description of the

organization represented, should be

received no later than 5 pm on May 3,

2000. Only one representative of an

organization may present oral

comments.

Any person attending the meeting

who does not request an opportunity to

speak in advance of the meeting may be

considered for oral presentation, if time

permits, and at the discretion of the

Chairperson. In addition, written

comments may be submitted to Dr.

Hahin at the address listed above up to

ten calendar days (May 19, 2000)

following the meeting.

Copies of the meeting agenda and the

roster of members will be furnished

upon request by Dr. Richard Nahin,

Executive Secretary, NACCAM,National

Institutes of Health, Building 31, Room

5B36, 31 Center Drive, Bethesda, MD

20892; (301) 594–2013, Fax 301–480–

9500.

Dated: April 17, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy, NIH.

[FR Doc. 00–10170 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center For Research

Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Research Resources Special Emphasis Panel

Biomedical Technology.

Date: April 20, 2000.

Time: 10 a.m. to 11 a.m.

Agenda: To review and evaluate grant

applications.

Place: Office of Review, National Center for

Research Resources, 6705 Rockledge Drive,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Rebecca A. Fuldner, PhD,

Scientific Review Administrator, Office of

Review, National Center for Research

Resources, 6705 Rockledge Drive, MSC 7965,

Room 6018, Bethesda, MD 20892–7965, (301)

435–0809.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333;

93.371, Biomedical Technology; 93.389,

Research Infrastructure, National Institutes of

Health, HHS)

Dated: April 17, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–10176 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research;

Notice of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Advisory Council for Nursing

Research.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contract Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections 552b(c)4)

and 552b(c)(6), Title 5 U.S.C., as

amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Advisory

Council for Nursing Research.

Date: May 23–24, 2000.

Open: May 23, 2000, p.m. to 5:00 p.m.

Agenda: For discussion of program policies

and issues.

Place: Natcher Building, Conference Room

D, 45 Center Drive, Bethesda, MD 20892.

Closed: May 24, 2000, 9:30 a.m. to 1 p.m.

Agenda: To review and evaluate grant

applications.

Place: Natcher Building, Conference Room

D, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Mary Leveck, Phd,

Associate Director for Scientific Programs,

NINR, NIH, Building 31, Room 5B05,

Bethesda, MD 20892, (303) 594–5963.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.361, Nursing Research,

National Institutes of Health, HHS)

Dated: April 14, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–10168 Filed 4–21–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Neurological

Disorders and Stroke; Notice of

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Advisory Neurological

Disorders and Stroke Council.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the